SGMO
Sangamo Therapeutics Inc
NASDAQ: SGMO · HEALTHCARE · BIOTECHNOLOGY
$0.14
+2.09% today
Updated 2026-06-05
Market cap
$55.93M
P/E ratio
—
P/S ratio
1.62x
EPS (TTM)
$-0.38
Dividend yield
—
52W range
$0 – $1
Volume
10.9M
WallStSmart proprietary scores
22
out of 100
Grade: F
Strong Sell
Investment rating
2.7
Growth
F5.0
Quality
C+2.5
Profitability
F5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$3.75
+2649.27%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-24.42M
- Revenue declining -77.60% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $111.30M | $176.23M | $57.80M | $39.55M | $34.56M |
| Net income | $-192.28M | $-257.83M | $-97.94M | $-122.93M | $-37.42M |
| EPS | — | — | — | — | $-0.38 |
| Free cash flow | $-243.80M | $-246.00M | $-67.41M | $-97.31M | $-24.42M |
| Profit margin | -172.76% | -146.30% | -169.45% | -310.81% | — |
Peer comparison
Smart narrative
Sangamo Therapeutics Inc trades at $0.14. Our Smart Value Score of 22/100 indicates the stock is weak. TTM revenue stands at $34.56M.
Frequently asked questions
What is Sangamo Therapeutics Inc's stock price?
Sangamo Therapeutics Inc (SGMO) trades at $0.14, on a P/S of 1.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Sangamo Therapeutics Inc overvalued?
Sangamo Therapeutics Inc carries a Smart Value Score of 22/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Sangamo Therapeutics Inc (SGMO)?
The 12-month analyst consensus target is $3.75, about 2649.3% above the current $0.14. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Sangamo Therapeutics Inc's revenue?
Sangamo Therapeutics Inc's trailing twelve-month revenue is $34.56M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.62x
ROE-2,892.00%
Beta1.04
50D MA$0.26
200D MA$0.44
Shares out0.41B
Float0.41B
Short ratio—
Avg volume10.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—